Hangzhou Tigermed Consulting Co., Ltd
HNGZY
Other OTC4.45
USD
- -
- -
ISIN
US41044T1088
CUSIP
41044T108
Return %
Stock
S&P500
1Y
11.25
18.99
3Y
-42.80
64.75
5Y
-65.10
71.84
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Xiao Chun Cao
- Full Time Employees
- 11,130
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- No. 508, Lujiatan Street Hangzhou ZH People's Republic of China 310051
- IPO Date
- Jul 11, 2022
- Website
- tigermed.net
- Similar Companies
- Business
- Hangzhou Tigermed Consulting Co., Ltd. (300347.SZ/3347.HK; OTC:HNGZY) operates as a leading global contract research organization providing integrated research and development solutions for the biopharmaceutical and medical device industries; core services encompass preclinical development including medicinal chemistry, compound screening, drug metabolism and pharmacokinetics, safety and toxicology, bioanalytical, and chemistry manufacturing controls; clinical development offerings such as medical writing, clinical monitoring, regulatory affairs, data management and statistical analysis, decentralized clinical trials, site management, medical device and in vitro diagnostics trials, multi-region clinical trials, and vaccine trials; and additional capabilities like pharmacovigilance, medical translation, quality assurance, GMP consulting, central laboratories, functional service provision, patient recruitment, electronic data capture systems, and remote follow-up. The company serves pharmaceutical, biotechnology, and medical device firms across phases I to IV of clinical trials, with technical support for registration, on-site services, and data analysis; it targets innovative drugs, generics, and devices in therapeutic areas including endocrinology, nervous system diseases, immune disorders, neoplasms, and more. Founded on December 15, 2004, and headquartered in Hangzhou, China, Tigermed maintains an international headquarters in Hong Kong and operates through over 100 subsidiaries and 180 locations in more than 50 countries across Asia-Pacific, Europe, North and South America, and Africa, employing over 10,000 staff. Recent developments include the 2023 opening of its Hong Kong international headquarters to bolster global coordination; the 2024 full-year results announcing 7.3% growth in new bookings, 12% backlog increase, and support for 28 Class I new drug and 6 innovative medical device approvals alongside 831 ongoing drug trials and 614 device/IVD projects; acquisition of Medical Edge in 2024; and completion of the acquisition of Japanese CRO Micron Inc. in July 2025, integrating it into Tigermed Japan to enhance medical imaging, clinical services, and Asia-Pacific expansion.